hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06354348, orgStudyIdInfo id: GastrectomyUSG, briefTitle: Practical Ultrasonographic Detection of Sarcopenia in Patients With Long-term Gastrectomy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-06, primaryCompletionDateStruct date: 2024-03-30, completionDateStruct date: 2024-03-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, class: OTHER, descriptionModule briefSummary: The investigators aimed to evaluate long-term sarcopenia in patients with total and distal gastrectomy by measuring the anterior thigh muscle with USG, which is a more specific and easy method., conditionsModule conditions: Sarcopenia, conditions: Gastrectomy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ACTUAL, armsInterventionsModule interventions name: USG, Grip strength, Chair stand test (CST), outcomesModule primaryOutcomes measure: Sarcopenia (Sonographic thigh adjustment ratio (STAR) was calculated by dividing the anterior thigh muscle thickness (mm) by BMI ), eligibilityModule sex: ALL, minimumAge: 45 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06354335, orgStudyIdInfo id: 1-16-02-62-20, briefTitle: Impact of a Major Organizational Change on Employee Productivity and Mental Health, acronym: PRO-MENTA, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2022-03-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Aarhus University Hospital, class: OTHER, collaborators name: University of Aarhus, collaborators name: Herning Hospital, collaborators name: Bispebjerg Hospital, descriptionModule briefSummary: The study investigates the short- and long-term impact of a major organizational change on employee health and productivity. Changes in organizations is a common aspect of modern work life in all sectors and public healthcare is no exception. However, emerging evidence suggests that organizational changes may be a potential stressor which can impact on employee well-being and contribute to stress-related health problems. Using a large-scale natural experiment, the overall aim of the study is to investigate the impact of a major organizational change that took place during 2016-19 on employee health and productivity. In addition, we aim to identify groups that may be at increased risk of experiencing negative consequences of the reorganization. These at-risk groups can in turn be candidates for extended preventive measures when planning future major organizational changes., conditionsModule conditions: Work Related Stress, conditions: Mental Health Issue, conditions: Work-related Illness, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 31555, type: ACTUAL, armsInterventionsModule interventions name: Employees exposed to a major hospital reorganisation, outcomesModule primaryOutcomes measure: Employee health measured by rate of absenteeism, use of health care services and redeemed drug prescriptions, secondaryOutcomes measure: Workplace productivity measured by number of patient contacts and medical procedures, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aarhus University Hospital, city: Aarhus, state: Central Denmark Region, zip: 8200, country: Denmark, geoPoint lat: 56.15674, lon: 10.21076, hasResults: False
protocolSection identificationModule nctId: NCT06354322, orgStudyIdInfo id: APHP230630, briefTitle: Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis, acronym: IPHYGENI MAI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2034-05, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Patients with autoinflammatory diseases (AID) have recurrent episodes of systemic inflammation accompanied by nonspecific elevation of blood inflammation markers typically absent between attacks. A complication of autoinflammatory diseases is AA amyloidosis, which can lead to renal failure and dialysis. Advances in genetic analysis have led to the identification of new autoinflammatory diseases and thus new pathophysiological pathways.However, genetic analyses are sometimes confronted with results that are difficult to interpret. These are the Variants of Unknown Significance, for which genetic analysis alone does not allow to determine if the genetic mutation is responsible for the symptoms.genetic analysis sometimes has limitations in the diagnosis of AID which can only be overcome by pathophysiological studies of the variants found., conditionsModule conditions: AA Amyloidosis, conditions: Autoinflammatory Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Exploration of VUS in AutoInflammatory Diseases, secondaryOutcomes measure: Pathophysiology of Autoinflammatory Diseases, secondaryOutcomes measure: Role of other innate immune cells in AutoInflammatory Diseases, secondaryOutcomes measure: Improve knowledge of AA amyloidosis, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06354309, orgStudyIdInfo id: vr_study, briefTitle: The Impact of Immersive Virtual Reality Training on Adult: Motion Sickness, and Ocular Surface: A Pilot Study, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-08-01, primaryCompletionDateStruct date: 2023-10-20, completionDateStruct date: 2023-10-20, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: He Eye Hospital, class: OTHER, descriptionModule briefSummary: The research project titled "The Impact of Immersive Virtual Reality Training on Adult: Motion Sickness, and Ocular Surface: A Pilot Study" aimed to evaluate the initial safety impact of head-mounted virtual reality (HMVR) devices with virtual reality amblyopia training games on postural stability, motion sickness, and ocular surface in healthy adult participants. 38 adults (76 eyes) with normal corrected vision and stereo vision were recruited. All subjects used HMVR device for two consecutive training sessions (30 minutes each, 10 minutes intervals). Before training, after the first training and the second training, recorded the results including best corrected visual acuity (BCVA), ocular position, stereo vision, postural stability, non-invasive tear breakup time (NITBUT), tear meniscus height (TMH), red eye analysis, lipid layer classification (TFLL), eye blink frequency, eye surface temperature, simulator sickness questionnaire (SSQ) score, ocular surface disease index (OSDI) dry eye questionnaire score, visual quality questionnaire score and visual fatigue questionnaire score., conditionsModule conditions: Amblyopia, conditions: Motion Sickness, conditions: Dry Eye, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 38, type: ACTUAL, armsInterventionsModule interventions name: Virtual reality game, outcomesModule primaryOutcomes measure: Simulator Sickness Questionnaire Score, secondaryOutcomes measure: Postural stability, secondaryOutcomes measure: Non-invasive tear breakup time, secondaryOutcomes measure: Tear meniscus height, secondaryOutcomes measure: Lipid layer classification, secondaryOutcomes measure: Eye blink frequency, secondaryOutcomes measure: Eye surface temperature, secondaryOutcomes measure: Ocular surface disease index dry eye questionnaire score, secondaryOutcomes measure: Visual quality questionnaire score, secondaryOutcomes measure: Visual fatigue questionnaire score, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: He Eye Hospital, city: Shenyang, state: Liaoning, zip: 110034, country: China, geoPoint lat: 41.79222, lon: 123.43278, hasResults: False
protocolSection identificationModule nctId: NCT06354296, orgStudyIdInfo id: CAF2024, briefTitle: Comparison of the Accuracy of Different Intraocular Lens Power Calculation Formulas in Cataract Patients With Prior Radial Keratotomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-08-15, completionDateStruct date: 2024-08-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: He Eye Hospital, class: OTHER, descriptionModule briefSummary: The Web-based Barret True K formula with no history formula has been proven to be a good choice for cataract patients after RK in several studies. The American society of cataract and refractive surgeons provides several IOL formulas for cataract patients who have undergone previous corneal refractive surgery. In cases where only IOL-Master data are available, Holladay 1 (Double-K) \[Holladay 1 (D-K)\] can be used for IOL power calculation in cataract patients with a history of RK. The traditional Haigis formula has also been shown to be effective for cataract patients after RK. To compare the accuracy of four intraocular lens (IOL) power calculation formulas in cataract patients after RK. They are Barrett True-K formula, Holladay 1(D-K) formula, Haigis formula, and MM formula., conditionsModule conditions: Cataract, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, outcomesModule primaryOutcomes measure: Accuracy of the IOL formula, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06354283, orgStudyIdInfo id: Progresif, briefTitle: Progressive Muscle Relaxation Exercises Women With Low Sexual Satisfaction Sexual Satisfaction and Functioning of Women and Their Partners, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-04-10, primaryCompletionDateStruct date: 2024-01-30, completionDateStruct date: 2024-02-08, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Halic University, class: OTHER, descriptionModule briefSummary: This study was conducted to investigate the effect of progressive muscle relaxation exercises on sexual satisfaction and functioning of women and their partners in women with low sexual satisfaction.Method: The single-blind, randomized controlled study was conducted between April 2023 and January 2024. The sample of the study was women with low sexual satisfaction and their partners were randomized into two groups as intervention and control. Each group consisted of 120 couples, n=60. The women in the intervention group were given progressive muscle relaxation techniques three times a week for four weeks. The results of the study focused on the effect on sexual satisfaction and functioning of men and women., conditionsModule conditions: Women With Low Sexual Satisfaction, conditions: Partners of Women With Low Sexual Satisfaction, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Intervention Group and Control Group, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: The progressive relaxation intervention and follow-up was conducted by the researcher who was not blinded to the interventions (PSI). Randomization was performed by another academic who was not an investigator in the study. In order to avoid bias, the researcher who conducted the intervention did not participate in any step of the pre-test, post-test and statistical evaluation process. Group information was not shared with the statistician who performed the analysis., whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ACTUAL, armsInterventionsModule interventions name: Progressive Muscle Relaxation Exercises, outcomesModule primaryOutcomes measure: Sexual Satisfaction, secondaryOutcomes measure: Sexual Function, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule locations facility: Fatma Şule Bilgiç, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06354270, orgStudyIdInfo id: 300104, briefTitle: A Clinical Study to Evaluate the Anti-Sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity Sufferers, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-04-11, primaryCompletionDateStruct date: 2024-06-24, completionDateStruct date: 2024-06-24, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: HALEON, class: INDUSTRY, descriptionModule briefSummary: The aim of this study is to confirm the clinical Dentin Hypersensitivity (DH) efficacy of a 0.454 percent (%) Stannous Fluoride (SnF2) toothpaste., conditionsModule conditions: Dentin Sensitivity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 115, type: ACTUAL, armsInterventionsModule interventions name: Stannous fluoride toothpaste, interventions name: Regular fluoride toothpaste (Crest Cavity Protection), outcomesModule primaryOutcomes measure: Change from Baseline in Schiff Sensitivity Score at Day 56, secondaryOutcomes measure: Change from Baseline in Tactile Threshold at Day 56, secondaryOutcomes measure: Change from Baseline in Schiff Sensitivity Score at Day 28, secondaryOutcomes measure: Change from Baseline in Tactile Threshold at Day 28, secondaryOutcomes measure: Change from Baseline in Impact on Everyday Life (Section 1 of Dentin Hypersensitivity Experience Questionnaire [DHEQ-48], Question [Q]7-9) at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Total Score (Section 2, Q1-34) at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Restrictions Domain (Section 2, Q1-4) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Adaptation Domain Score (Section 2, Q5-16) at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Social Impact Domain (Section 2, Q17-21) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Emotional Impact Domain (Section 2, Q22-29) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in DHEQ Identity Domain (Section 2, Q30-34) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in Global Oral Health (Section 2, Q35) Score at Days 28 and 56, secondaryOutcomes measure: Change from Baseline in Effect on Life Overall (Section 2, Q36-39) Score at Days 28 and 56, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Family and Cosmetic Dentistry, All Sums Research Center Ltd., city: Melbourne, state: Florida, zip: 32940, country: United States, geoPoint lat: 28.08363, lon: -80.60811, hasResults: False
protocolSection identificationModule nctId: NCT06354244, orgStudyIdInfo id: 2023-183-KY-02, briefTitle: Electroacupuncture of Different Treatment Frequency in Chronic Urinary Retention Caused by Lower Motor Neuron Lesions, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Guang'anmen Hospital of China Academy of Chinese Medical Sciences, class: OTHER, descriptionModule briefSummary: The aim of this study is to compare the effects of electroacupuncture of different frequency in patients with chronic urinary retention caused by lower motor neuron lesions, conditionsModule conditions: Urinary Retention, conditions: Lower Motor Neurone Lesion, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Electroacupuncture of 2 sessions per week, interventions name: Electroacupuncture of 3 sessions per week, interventions name: Electroacupuncture of 4 sessions per week, outcomesModule primaryOutcomes measure: The response rate., secondaryOutcomes measure: The response rate., secondaryOutcomes measure: The change in post void residuals (PVR) from baseline., secondaryOutcomes measure: The change in the proportion of patients reporting severe urinating difficulty from baseline., secondaryOutcomes measure: The change in the proportion of patients having stool retention from baseline., secondaryOutcomes measure: The change in the proportion of patients requiring catheterization from baseline., secondaryOutcomes measure: The proportion of patients reporting much better or moderately better regarding the Patient Global Impression of Improvement (PGI-I)., secondaryOutcomes measure: The proportion of patients having recurrent symptomatic UTI, hydroureter, or hydronephrosis., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Guang'anmen Hospital, China Academy of Chinese Medical Sciences, status: RECRUITING, city: Beijing, country: China, contacts name: Zhishun Liu, PhD, role: CONTACT, phone: +861088002331, email: zhishunjournal@163.com, contacts name: Min Yang, role: CONTACT, phone: +8618810268077, email: yangmin2019@yeah.net, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06354231, orgStudyIdInfo id: RC48-C012, briefTitle: DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-20, primaryCompletionDateStruct date: 2026-12-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: Approximately 20 participants will be enrolled in the study to evaluate the efficacy and safety of the combination of DV (DV, 2.0 mg/kg, intravenously administered every 2 weeks) and toripalimab (toripalimab, 3.0mg/kg, intravenously administered every 2 weeks). Subjects will receive 6 cycles of DV and toripalimab, followed by laser surgery to remove ureteral or renal pelvis tumors, followed by 12 cycles of DV and 1 year of toripalimab consolidation therapy. Efficacy and safety were evaluated by cystoscopy, ureteroscopy, laboratory tests, and imaging examinations after treatment., conditionsModule conditions: Renal Insufficiency, conditions: Upper Urinary Tract Urothelial Carcinoma, conditions: Solitary Kidney, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: DV, interventions name: Toripalimab, interventions name: Laser surgery, outcomesModule primaryOutcomes measure: Kidney-intact disease-free survival, KI-DFS, secondaryOutcomes measure: Time to progression, TTP, secondaryOutcomes measure: Time to RNU, secondaryOutcomes measure: Disease-specific survival time, DSS, secondaryOutcomes measure: Overall survival, secondaryOutcomes measure: 3m complete remission, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, country: China, contacts name: dingwei ye, role: CONTACT, phone: 64175590-82800, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06354218, orgStudyIdInfo id: GXL-005, briefTitle: Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-01, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: This study is a Single Arm, Prospective, Exploratory, Single Center Phase II Clinical Study to evaluate the effectiveness of the combination of Serplulimab and Concurrent Chemoradiotherapy in the treatment of elderly patients with locally advanced esophageal cancer who cannot be treated surgically.Subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria., conditionsModule conditions: Esophageal Carcinoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Serplulimab, outcomesModule primaryOutcomes measure: mPFS, secondaryOutcomes measure: ORR, secondaryOutcomes measure: OS, secondaryOutcomes measure: DOR, secondaryOutcomes measure: Toxic side reactions, eligibilityModule sex: ALL, minimumAge: 75 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Nanjing Medical University, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210009, country: China, contacts name: Xiaolin MM Ge, PHD, role: CONTACT, phone: 13951818797, email: doctorsxl@163.com, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False